1. Volume 149, Issue 3, Pages 498-505 (June 2018)
The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results 
Mark H. Stoler, Thomas C. Wright, Valentin Parvu, Laurence Vaughan, Karen Yanson, Karen Eckert, Tobi Karchmer, Salma Kodsi, Charles K. Cooper 
Gynecologic Oncology 
Volume 149, Issue 3, Pages (June 2018)
DOI: /j.ygyno
Copyright © 2018 The Authors Terms and Conditions

2. Gynecologic Oncology 2018 149, 498-505DOI: (10.1016/j.ygyno.2018.04.007)
Copyright © 2018 The Authors Terms and Conditions

3. Fig. 1
Subject reconciliation during baseline enrollment and participation in this trial. Abbreviations: ≥ASC-US, atypical squamous cells of undetermined significance or greater; CIN, cervical intraepithelial neoplasia; hrHPV, high-risk human papillomavirus; NILM, negative for intraepithelial lesions or malignancies; neg, negative; p16, p16INK4A protein; PI, principal investigator; pos, positive; UNSAT, unsatisfactory cytology.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions